These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25151364)

  • 21. Long-term clinical outcome of bilateral pallidal stimulation for intractable craniocervical dystonia (Meige syndrome). Report of 6 patients.
    Sobstyl M; Brzuszkiewicz-Kuźmicka G; Zaczyński A; Pasterski T; Aleksandrowicz M; Ząbek M
    J Neurol Sci; 2017 Dec; 383():153-157. PubMed ID: 29246604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facial dystonia: clinical features, prognosis and pharmacology in 31 patients.
    Defazio G; Lamberti P; Lepore V; Livrea P; Ferrari E
    Ital J Neurol Sci; 1989 Dec; 10(6):553-60. PubMed ID: 2515166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
    Pullman SL; Greene P; Fahn S; Pedersen SF
    Arch Neurol; 1996 Jul; 53(7):617-24. PubMed ID: 8929169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin A--injection for cervical dystonia.
    Bhaumik S; Behari M
    J Assoc Physicians India; 1999 Mar; 47(3):267-70. PubMed ID: 10999117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time course of distant effects of local injections of botulinum toxin.
    Garner CG; Straube A; Witt TN; Gasser T; Oertel WH
    Mov Disord; 1993; 8(1):33-7. PubMed ID: 8380486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs of treating dystonias and hemifacial spasm with botulinum toxin A.
    Dodel RC; Kirchner A; Koehne-Volland R; Künig G; Ceballos-Baumann A; Naumann M; Brashear A; Richter HP; Szucs TD; Oertel WH
    Pharmacoeconomics; 1997 Dec; 12(6):695-706. PubMed ID: 10175981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE; Fahn S
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe tongue protrusion dystonia: clinical syndromes and possible treatment.
    Schneider SA; Aggarwal A; Bhatt M; Dupont E; Tisch S; Limousin P; Lee P; Quinn N; Bhatia KP
    Neurology; 2006 Sep; 67(6):940-3. PubMed ID: 17000958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
    Mauriello JA; Dhillon S; Leone T; Pakeman B; Mostafavi R; Yepez MC
    Br J Ophthalmol; 1996 Dec; 80(12):1073-6. PubMed ID: 9059273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of botulinum toxin in Meige's disease.
    Maurri S; Brogelli S; Alfieri G; Barontini F
    Riv Neurol; 1988; 58(6):245-8. PubMed ID: 3247565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of treatment with botulinum toxin on neurogenic blepharospasm.
    Elston JS; Russell RW
    Br Med J (Clin Res Ed); 1985 Jun; 290(6485):1857-9. PubMed ID: 3924284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin.
    Van den Bergh P; Francart J; Mourin S; Kollmann P; Laterre EC
    Muscle Nerve; 1995 Jul; 18(7):720-9. PubMed ID: 7783762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion.
    Lim EC; Seet RC
    Acta Neurol Scand; 2008 Feb; 117(2):73-84. PubMed ID: 17850405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripherally induced oromandibular dystonia.
    Sankhla C; Lai EC; Jankovic J
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):722-8. PubMed ID: 9810945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trihexyphenidyl in posthemorrhagic dystonia: motor and language effects.
    Pidcock FS; Hoon AH; Johnston MV
    Pediatr Neurol; 1999 Mar; 20(3):219-22. PubMed ID: 10207932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oromandibular dystonia and botulinum toxins].
    Van Durme B; Loeb I; Van Reck J
    Acta Stomatol Belg; 1996 Mar; 93(1):37-41. PubMed ID: 9005716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Local injection treatment with botulinum toxin A in blepharospasm, Meige syndrome and hemifacial spasm. Observations in 106 patients].
    Ceballos-Baumann AO; Gasser T; Dengler R; Oertel WH
    Nervenarzt; 1990 Oct; 61(10):604-10. PubMed ID: 2274092
    [No Abstract]   [Full Text] [Related]  

  • 40. DYT16: the original cases.
    Camargos S; Lees AJ; Singleton A; Cardoso F
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):1012-4. PubMed ID: 22842711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.